Brian M.Sibling Capital Ven... Net Worth

The estimated Net Worth of Brian M.Sibling Capital Ven... is at least $50.9 ezer dollars as of 2 July 2018. Brian Ven owns over 463,158 units of Tricida Inc stock worth over $50,947 and over the last 6 years Brian sold TCDA stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Brian Ven TCDA stock SEC Form 4 insiders trading

Brian has made over 1 trades of the Tricida Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently Brian bought 463,158 units of TCDA stock worth $8,800,002 on 2 July 2018.

The largest trade Brian's ever made was buying 463,158 units of Tricida Inc stock on 2 July 2018 worth over $8,800,002. On average, Brian trades about 463,158 units every 0 days since 2018. As of 2 July 2018 Brian still owns at least 463,158 units of Tricida Inc stock.

You can see the complete history of Brian Ven stock trades at the bottom of the page.

What's Brian Ven's mailing address?

Brian's mailing address filed with the SEC is 420 W Market St, San Antonio, TX 78205, USA.

Insiders trading at Tricida Inc

Over the last 6 years, insiders at Tricida Inc have traded over $198,373,537 worth of Tricida Inc stock and bought 7,174,449 units worth $105,536,837 . The most active insiders traders include David P Bonita, Advisors Llc Orbi Med Capit... és Healthcare Capital Partners.... On average, Tricida Inc executives and independent directors trade stock every 8 days with the average trade being worth of $22,553. The most recent stock trade was executed by Robert J Alpern on 23 November 2022, trading 131,879 units of TCDA stock currently worth $27,695.

What does Tricida Inc do?

Complete history of Brian Ven stock trades at Tricida Inc

Tricida Inc executives and stock owners

Tricida Inc executives and other stock owners filed with the SEC include:

• Gerrit Klaerner,
  President, Chief Executive Officer, Director
• Dawn Parsell,
  Executive Vice President - Clinical Development
• Geoffrey Parker,
  Chief Financial Officer, Executive Vice President
• Edward Hejlek,
  Senior Vice President
• Dr. Gerrit Klaerner Ph.D.,
  Founder, Pres, CEO & Exec. Director
• Dr. Dawn Parsell Ph.D.,
  Exec. VP of Clinical Devel.
• Geoffrey M. Parker,
  COO, CFO & Exec. VP
• Robert L. McKague J.D.,
  Exec. VP, Company Sec., Gen. Counsel & Chief Compliance Officer
• Dr. Wilhelm Stahl,
  Exec. VP & CTO
• Klaus Veitinger,
  Independent Chairman of the Board
• David Bonita,
  Independent Director
• Kathryn Falberg,
  Independent Director
• David Hirsch,
  Independent Director
• Sandra Coufal,
  Independent Director
• Robert Alpern,
  Independent Director
• Marc Cobo,
  Senior Vice President - Finance, Chief Accounting Officer
• Robert McKague,
  Executive Vice President, General Counsel, Secretary
• Edward J. Hejlek Esq., J.D.,
  Exec. VP of Intellectual Property
• Jackie Cossmon,
  VP of Investor Relations & Communications
• Annie Yoshiyama,
  VP of Fin. & Chief Accounting Officer
• Claire Lockey,
  Chief Dev. Officer and Sr. VP
• Brian M.Sibling Capital Fun...,
  
• Brian M.Sibling Capital Fun...,
  
• Brian M.Sibling Capital Ven...,
  
• Beek Jeroen B Van,
  Chief Comm Officer and Sr VP
• Steffen Pietzke,
  VP Fin & Chief Acct Officer
• Capital Partners Ii, Llc Lo...,
  
• Advisors Llc Orbi Med Capit...,
  
• Harbor Master Investors (Ca...,
  10% owner
• Wilhelm Stahl,
  EVP, Chief Tech Officer
• Brian M.Sibling Capital Ven...,
  
• Susannah Cantrell,
  EVP, Chief Comm. Officer
• Brian M.Sibling Capital Fun...,
  
• Brian M.Sibling Capital Fun...,
  
• Annie Yoshiyama,
  Senior VP, Finance and CAO
• Healthcare Capital Partners...,